Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Cited by 24 Publications

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Cell Rep, 2019, 26(6):1544-1556

PubMed: 30726737 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

J Lipid Res, 2019, 60(6):1078-1086

PubMed: 30962310 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1965

PubMed: 30530705 ( click the link to review the publication )

Leukemia, 2018, 32(3):616-625

PubMed: 28904384 ( click the link to review the publication )

Chemosphere, 2018, 210:467-475

PubMed: 30025364 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Drugs R D, 2017, 17(2):287-296

PubMed: 28299646 ( click the link to review the publication )

Cell Death & Disease, 2017, 10.1038/cddis.2017.454

PubMed: ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1335-1351

PubMed: 28496304 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):63

PubMed: 28877739 ( click the link to review the publication )

Lipids Health Dis, 2016, 15:152

PubMed: 27613245 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(10):909-919

PubMed: 27358112 ( click the link to review the publication )

Cell Rep, 2015, 13(11):2353-2361

PubMed: 26686626 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Targets

Microtubules ^[1]
(Cell-free assay)

32 μM

In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with K_i of 85 nM. ^[1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. ^[2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. ^[4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NFnDe3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXfsWIt6OC1yLkWg{txO	NHj1TIwzPCCq		NXHvcHZ4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=	M3rhb\|I2PjZ\|N{[5
HepG2-HBV1.1	MlnIRZBweHSxc3nzJGF{e2G7	M{nQUVAuOC53IN88US=>	MYSyOEBp		NVOwUY8zcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4rKVlI2PjZ\|N{[5
HepG2.2.15	NUDjV\|lUTnWwY4Tpc44hSXO\|YYm=	Ml;GNE4yKM7:TR?=	MYCyOEBp		MYHwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36=	MknaNlU3PjN5Nkm=
HepG2-HBV1.1	NVfFUIhyTnWwY4Tpc44hSXO\|YYm=	MXewMlEh\|ryP	M2e2PVI1KGh?		M2HOU5Bzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW\|c3nvci=>	MkniNlU3PjN5Nkm=
HepG2-HBV1.1	MWHGeY5kfGmxbjDBd5NigQ>?	NXfBRXhnOC5zIN88US=>	MVK0PEBp		Mn3ydJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW\|IFThcoUheGG{dHnjcIV{	NEjXUnEzPTZ4M{e2PS=>
HepG2-HBV1.1	NEX1W\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjCe3AxNjFizszN	NIPWb4gyNTViZB?=		MUPpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	NG\heJczPTZ4M{e2PS=>
HepG2-HBV1.1	M4DLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfDNE4yKM7:TR?=	NHqxdVQyNTViZB?=		NYW5dHFbcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	M1TBcFI2PjZ\|N{[5
HepG2-HBV1.1	M1[5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jqRVAvOSEQvF2=	NVfZNXQ3OTJvN{KgbC=>		NHvhcFFqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	NEHQZ4IzPTZ4M{e2PS=>
HepG2-HBV1.1	MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUS3bG5JOC5zIN88US=>	M{\PZlEzNTd{IHi=		MUnpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JHMueGijc3W=	MlvrNlU3PjN5Nkm=
Raji	NFPPfYxHfW6ldHnvckBCe3OjeR?=	MUSwMlXDqM7:TR?=	NHvoO\|A4OiCq		MXrhZo9tcXOqZYOgZZV1d3CqYXf5xsA>	M1POelI2PDR4M{e3
SK-MEL-28	MnGwSpVv[3Srb36gRZN{[Xl?	MlLJN\|Ahdk1?	M13VcVYhcA>?		NFLndXlqdmS3Y3XzJGcz6oDVTTDj[YxtNWO7Y3zlJIFzemW\|dB?=	MXiyOVMyOzBzMB?=
H157	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rONWlEPTB;MT6wN{DDuSByLkC0JI1qfTKP	MX2yOVI2PzlzMR?=
Jurkat	M3ThZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGxMVMhdk1?	NXThfFF3PDkEoHi=	M2rlb2ROW09?	NXzDXZdx\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>?	NU\mb20{OjVzNU[xOFY>
CEM	Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jBN\|EuOyCwTR?=	MVG0POKhcA>?	NUDlSIVJTE2VTx?=	M3zzZ4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	NHXie3czPTF3NkG0Oi=>
P12	NUjKXVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGxMVMhdk1?	MnfvOFjDqGh?	M1;0[GROW09?	NInid41l\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6	MXGyOVE2PjF2Nh?=
KB	NYDLOlVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\0WZNKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN	NHvRPI0zPTB3OEWyOi=>
KBv200 (ABCB1)	NVTveoszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLKTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?=	MV2yOVA2QDV{Nh?=
SUDHL6	M4XtR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrxNgKBkc7:TR?=	NGjlZ3Q1QC95MjDo		NHzObldqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	MYCyOFk3OTZyNB?=
SUDHL6	NVHkZWs{TnWwY4Tpc44hSXO\|YYm=	NX;6UHdkOeLCid88US=>	NFXTSYw4OiCq		NFnweXVqdmS3Y3XzJJNq\26rZnnjZY51KGGyb4D0c5Rq[yCvb4LwbI9td2e7IHPoZY5o\XNiY3;0doV{fGWmIIfpeIghSkOOMUHBJJNqWk6D	NFrhOGYzPDl4MU[wOC=>
HCT-116	NXXTVoFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnHTVUxRTVibl2=	M4[4RlI1QTJ5OEW3
SKNBe2C	M{nyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmL2TWM2OD1\|Mj64xtE1NjBibl2=	MWqyOFkzOTl{MB?=
IGNR91	M{j2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\pdWlEPTB;MkSuN:KyOS55IH7N	NEXHPZIzPDl{MUmyNC=>
SKNAS	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfJPYhKSzVyPUGuOeKyOC5{IH7N	NF3DbZEzPDl{MUmyNC=>
LAN1	M1;JZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTJwM9MxNE4zKG6P	M1LhSFI1QTJzOUKw
SHSY5Y	NYG4fIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXMTWM2OD16LkNCtVAvPiCwTR?=	NXP2TVhPOjR7MkG5NlA>
A549-WT	NUm0bVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLYTWM2OD1zOT60N\|chyrFiMD61PVQhKG6P	NVvrc\|FpOjR6NUi4Nlc>
A549-R	NUXicZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4C2fWlEPTB;MUKuNVc5KMLzIECuN\|M{KCCwTR?=	NXnR[lZoOjR6NUi4Nlc>
MCF-7-WT	M3fEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2e3O2lEPTB;MUeuO\|UzKMLzIECuNlE5KCCwTR?=	NUHC[5NHOjR6NUi4Nlc>
MCF-7-R	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfqTWM2OD13LkWzPUDDuSByLkG0OEAhdk1?	NUOwe4pPOjR6NUi4Nlc>
A549-R	NYf4c\|FyS3m2b4TvfIlkcXS7IFHzd4F6				NIC0OXNKSzVyPUGyMlE4QCEEsTCwMlM{OyCwTR?=	MXyyOFg2QDh{Nx?=
MCF-7-R	MUDDfZRwfG:6aXPpeJkhSXO\|YYm=				Mom5TWM2OD13LkWzPUDDuSByLkG0OEBvVQ>?	NFX5Xo8zPDh3OEiyOy=>
SW620	MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPZfVBKSzVyPUeuPFAhyrFiMD6wPEBvVQ>?	MVSyOFczPjd\|OR?=
SW620/AD300	MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ewVGlEPTB;OUC5MlYxKMLzIEiuPVEhdk1?	NGKzRYUzPDd{NkezPS=>
HEK293/pcDNA3.1	NGLsOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwNEWgxtEhOC5{MDDuUS=>	NHXteVEzPDd{NkezPS=>
HEK293/ABCC1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe1bZVKSzVyPUG5MlI6KMLzIEKuNFghdk1?	MoTUNlQ4OjZ5M{m=
TCC	NGPYUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFPNXo4zPCCq		NXP5PYlNUUN3ME23NEBvVQ>?	M4m4SFI1PzF4OUS0
TCC	NIPK[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXq0PEBp		NHvIboJKSzVyPUWwJI5O	MUWyOFcyPjl2NB?=
HepG2/ADM	M3TyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFK4fWVKSzVyPUKuO\|g3O8LzMD6yN\|cyKM7:TR?=	NETBU3ozPDdyNEW1Oi=>
HepG2	NFX3O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXe4OpVLUUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2=	MWWyOFcxPDV3Nh?=
MCF-7/ADR	NFW2TnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;EXI82UUN3ME20MlQ5OjcEsUCuNlA4OCEQvF2=	NXjnb4hrOjR5MES1OVY>
MCF-7	NYj0O5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TufmlEPTB;MD6wNVU6yrFyLkCwOlIh\|ryP	MWiyOFcxPDV3Nh?=
A-172	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3wOXlIOC5zwrFOwG0>	MlzXNlQwPzJiaB?=		MmXEbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	M1rQXVI1PTNyMkO1
U-251MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGwMlHDqM7:TR?=	NGjUR3MzPC95MjDo		NILlXZhqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6	MmPENlQ2OzB{M{W=
DLD-1	NV7RUG46TnWwY4Tpc44hSXO\|YYm=	MkOyNVAxKG6P	MnnCOFghcA>?		M{H0VZBzd22xdHXzJHJWVlh\|IHTlcYV1cHmuYYTpc47DqA>?	MoDkNlQ1ODN2NUO=
CCD18Co	NI\Q[\|NHfW6ldHnvckBCe3OjeR?=	MmfoNVAxKG6P	MWm0PEBp		M4nidJBzd22xdHXzJHJWVlh\|IHTlcYV1cHmuYYTpc47DqA>?	M3rKdFI1PDB\|NEWz
DLD-1	NHzDWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjrNE0yODByIH7N	MmfrOFghcA>?		NGXubmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	M2CxN\|I1PDB\|NEWz
CCD18Co	NXTjXXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWOzbnluOC1zMECwJI5O	MlrrOFghcA>?		Mne0bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	NF;kWowzPDRyM{S1Ny=>
HepG2	NH70[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVm0TGxzOjRiaB?=		M2TXPGlEPTB;NUKuOgKBkc7:TR?=	M2rtW\|I1OzRzNki4
HEK293/pcDNA3.1	M{\qVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHGNplKSzVyPUCuNFA1yrFyLkCwNFMh\|ryP	NFHMTmwzPDJ6NEe4Ny=>
HEK293/MRP1	NHrjZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMEW1xtExNjBzMkCg{txO	MX:yOFI5PDd6Mx?=
Ramos	NELFT\|RCeG:ydH;zbZMhSXO\|YYm=	MX2y5qCK\|ryP	MXG0PEBp		Mnq1bY5lfWOnczCzOE43LcLzMT65NkUh[XCxcITvd4l{	NXPtXYpVOjR{NU[0PVE>
NCI-H1299/pcDNA3	MlfvR4VtdCCYaXHibYxqfHliQYPzZZk>	NYjiT202OC1{MDDuUS=>	NVnhNVlHQTZiaB?=		NUXqNJlOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NVLIbY9yOjRzN{ewNVI>
H1299/ICAM-3	M4r1OWNmdGxiVnnhZoltcXS7IFHzd4F6	MnnGNE0zOCCwTR?=	NEXaSGk6PiCq		MkmwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MnrJNlQyPzdyMUK=
NCI-H1299/pcDNA3	Mlm3SpVv[3Srb36gRZN{[Xl?	NYLSWGtROS93L{GwM\|IxyqCwTR?=	M3f0cFk3KGh?		NGiyWHhqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR	MUmyOFE4PzBzMh?=
H1299/ICAM-3	NYTtNok4TnWwY4Tpc44hSXO\|YYm=	M4jZR\|EwPS9zMD:yNOKhdk1?	M{DiTVk3KGh?		NVTI[XRucW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1\|LDC4MEA6NCCjbnSgVGFTWA>?	M3HXflI1OTd5MEGy
W1	NGTySnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3O5dGlEPTB;MD6wNFMzKM7:TR?=	Mm\rNlQyPDBzN{[=
W1VR	NHfQcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwMEW2JO69VQ>?	MkPCNlQyPDBzN{[=
K562	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\wTWM2OD1yLkCzNkDDuSByLkCwNUAh\|ryP	NX7CWmhiOjRzM{W5N\|c>
K562/ADR	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{GxfWlEPTB;Mz6yOlEhyrFiMD60NVIh\|ryP	NXLGd2RLOjRzM{W5N\|c>
K562	NHvCeJVCeG:ydH;zbZMhSXO\|YYm=	MnnFNE4{KM7:TR?=	M4rJV\|I1KGh?		MkCxbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	MWmyOFE{PTl\|Nx?=
K562/ADR	NFLwOIlCeG:ydH;zbZMhSXO\|YYm=	NV\6XotKOyEQvF2=	NHvKT3YzPCCq		MU\pcoR2[2W\|IHHwc5B1d3Orcx?=	MUOyOFE{PTl\|Nx?=
A549	NIXPS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXywU5dSUUN3ME2wMlExKMLzIECuNFMh\|ryP	NVnv[2pDOjN7N{GwO\|U>
K562	NFvWdVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MmLkN{44PeLCk{[wxsBvVQ>?	Mn\MO\|LDqGkEoB?=		Mmn2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MlXwNlM5Pzd{MkO=
lucena	NUHQc2ZbS2WubDDWbYFjcWyrdImgRZN{[Xl?	M3XL[FMvPzYkgKO2NOKhdk1?	NYWxepA{PzMEoHlCpC=>		M2XVWY5wKGWoZnXjeC=>	NVXrNoJqOjN6N{eyNlM>
FEPS	NITHSG9E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVOzMlc26oDVNkFCpI5O	MY[3NuKhcMLi		M2TDc45wKGWoZnXjeC=>	MXWyN\|g4PzJ{Mx?=
A2780	NUToWGdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXmOY5OUUN3ME2zMlUhdU1?	NUHpcHViOjN6MkmyNFM>
ACHN	M1voWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRDBwMTDtUS=>	NUjHUYF4OjN6MkmyNFM>
U-937	NHviRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLyRXRvUUN3MEyzOEBvVQ>?	NF7KWWIzOzh{OUKwNy=>
Jurkat	MU\BdI9xfG:\|aYOgRZN{[Xl?	NHPqepQ2yqEQvHevcYzDqA>?	MYKyOEBp		MlvYbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	M3XTfVI{QDFyNEC5
Jurkat	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYC1xsDPxGdxbX\|CpC=>	M1XHdlI1KGh?		MmPPZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn	NULw[HhiOjN6MUC0NFk>
Hep-2	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDSTWM2OD1yLkC0xtExNjBzIN88US=>	M1nuO\|I{PzhyNEK0
Hep-2/v	NGnQ[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3hSWJyUUN3ME2xMljDuTBwMkCg{txO	MnGzNlM4QDB2MkS=
SGC-7901	NETteWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;yNE0yOCEQvHevcYw>	NGjlVnUzPC92OD:3NkBp		NXHofHZScW6qaXLpeJMh[2WubDDndo94fGhiaX6g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	M1zadVI{PzR\|NUey
SGC-7901/VCR	NXS0VXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX3WplVOC1zMDFOwIcwdWx?	M13U[\|I1NzR6L{eyJIg>		NFrScGhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MWqyN\|c1OzV5Mh?=
SGC-7901	NF;we3dCeG:ydH;zbZMhSXO\|YYm=				NUC0c2F1cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	M2T0VVI{PzR\|NUey
SGC-7901/VCR	Mn;oRZBweHSxc3nzJGF{e2G7				NIfHepNqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	NWPydo1DOjN5NEO1O\|I>
KB-3-1	M{LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nXO2lEPTB;MT62OkDDuSByLkG2NkDPxE1?	NYLUOJRvOjN4N{O0OFU>
KB-C2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fHOWlEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2=	NHm3TGkzOzZ5M{S0OS=>
KB-3-1	NI\SXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnTT\|N5UUN3ME2xMlI3KMLzIECuNFI4KM7:TR?=	M{LjT\|I{Pjd\|NES1
KB-V1	NYHidWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEflSHVKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?=	MnHqNlM3PzN2NEW=
HEK293/pcDNA3.1	M375XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TmdmlEPTB;MkSuNUDDuSByLkKwOEDPxE1?	MVqyN\|Y4OzR2NR?=
HEK293/ABCB1	M1jSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjWZoVKSzVyPUO1NVIvQCEEsTCzO\|gvOzlzIN88US=>	MVmyN\|Y4OzR2NR?=
A549/EGFP	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DUWVAvODFvMUCwNEDPxE1?			MnjwTWM2OD16Nj63JOKyKDJ7LkGg{txO	NUHXVJB{OjN4M{SyPFI>
A549/Slug	NVq2UYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XUUVAvODFvMUCwNEDPxE1?			MlHaTWM2OD17LkegxtEhOy5zIN88US=>	NU\iZlF6OjN4M{SyPFI>
JFCR39	NEC0dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYOxJOK2VQ>?	MnLRNlQhcA>?	M3rwOmROW09?	MkXqcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG\|ZTDj[Yxtew>?	MWWyN\|U6QDJ5Nh?=
A549	NYLMeII2TnWwY4Tpc44hSXO\|YYm=	MlfTNVAxKG6P	MoLSNVYhcA>?	NUT3RmRrTE2VTx?=	M{\WWoxm[WS\|IITvJIEhdG:\|czDv[kBucWO{b4T1ZpVt\XN?	M1W0elI{PTl6Mke2
SGC7901	NFy0TG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLmV\|A5UUN3ME2xMlI36oDLwsJihKkxNjFzIN88[{9udA>?	MX:yN\|U3PDR6Mh?=
SGC7901/LV-NC	MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXn2PJBGUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>?	MYSyN\|U3PDR6Mh?=
SGC7901/LV-SGO1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fuS2lEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw>	NXXXWYxYOjN3NkS0PFI>
SGC7901/VCR	M{C1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3LXGJKSzV\|PUKwMlU{6oDLwsJihKkyNjl4IN88[{9udA>?	NW\0OWJROjN3NkS0PFI>
SGC7901/VCR-NC	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHwTWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw>	MXGyN\|U3PDR6Mh?=
SGC7901/VCR-si-SGO1	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTZwMUlihKnDueLCiUGuNFMh\|rypL33s	NYmzN5k6OjN3NkS0PFI>
SGC7901/ADR	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHhTWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=>	M1KwNFI{PTZ2NEiy
SGC7901/ADR-NC	M2rFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRThwOURihKnDueLCiUCuOlgh\|rypL33s	Mn60NlM2PjR2OEK=
SGC7901/ADR-si-SGO1	MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jCeGlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw>	MXqyN\|U3PDR6Mh?=
SH-SY5Y	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnBcpExNjByMT2xNEDPxE1?	M1\vT\|I1KGh?		MmXzTWM2OD1yLkGxN:KyOC5yMUKg{txO	NFj3NIczOzF{OUC2OS=>
SH-SY5Y	NYf4[HRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m2d\|AvODBzLUGwJO69VQ>?	NHfSPHA1QCCq		MUTJR\|UxRTBwMEe4xtExNjByOTFOwG0>	M1XFXlI{OTJ7ME[1
SH-SY5Y	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuwMlAxOS1zMDFOwG0>	MVO3NkBp		NU\NR\|duUUN3ME2wMlA2OcLzMD6wNFgh\|ryP	MWWyN\|EzQTB4NR?=
SH-SY5Y	MYHBdI9xfG:\|aYOgRZN{[Xl?	NEi2TWoxNjFizszN	NIXOdWYxNTJ2IHi=		M3vjeolv\HWlZYOgZZBweHSxc3nzJI9nKFOKLWPZOXkh[2WubIOg[o9tdG:5aX7nJINmdGxiY4njcIUh[XK{ZYP0JIF1KHSqZTDHNk9OKHCqYYPl	NFS2VYczOzF{OUC2OS=>
SH-SY5Y	M2XweGFxd3C2b4Ppd{BCe3OjeR?=	NFrPfnoxNjFizszN	M1TsSFAuOjRiaB?=		NIOwNFVqdmS3Y3XzJI1qfG:2aXOgZZJz\XO2wrC=	Mn\1NlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; PubMed: 26156322 J Hematol Oncol MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine	26156322
Growth inhibition assay	Cell viability ; PubMed: 26156322 J Hematol Oncol MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively. Cell viability was measured by MTT assay.	26156322

In vivo

Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. ^[6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . ^[7]

Protocol

Cell Research:^[1]	- Collapse Cell lines: B16 melanoma cell Concentrations: 10 nM Incubation Time: 3 days Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA. (Only for Reference)
Animal Research:^[6]	- Collapse Animal Models: Human rhabdomyosarcoma xenografts Rh12 Formulation: Water solutioin Dosages: 3 mg/kg Administration: A single i.p. administration (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: B16 melanoma cell
Concentrations: 10 nM
Incubation Time: 3 days
Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 10⁴ cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO₂ and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
(Only for Reference)

Animal Research:^[6]

- Collapse

Animal Models: Human rhabdomyosarcoma xenografts Rh12
Formulation: Water solutioin
Dosages: 3 mg/kg
Administration: A single i.p. administration
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vincristine sulfate SDF

Molecular Weight	923.04
Formula	C₄₆H₅₈N₄O₁₄S
CAS No.	2068-78-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Leurocristine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03981510	Recruiting	Diagnostic Test: 3D-Transit	Constipation\|Childhood Acute Lymphoblastic Leukemia\|Neurofibromatosis 1\|Chronic Constipation With Overflow	University of Aarhus	June 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Paclitaxel

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate

Cited by 24 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vincristine sulfate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vincristine sulfate

Cited by 24 Publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vincristine sulfate SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)